Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Veracyte Inc (VCYT)

Veracyte Inc (VCYT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Veracyte Inc 6000 SHORELINE COURT SUITE 300 SOUTH SAN FRANCISCO CA 94080 USA

www.veracyte.com Employees: 815 P: 650-243-6300 F: 650-243-6388

Description:

Veracyte, Inc. is a diagnostics company. It is focused on discovering, developing and commercializing molecular cytology solutions. The Company provides Afirma Thyroid FNA Analysis, which helps physicians in reducing unnecessary diagnostic surgeries for patients with thyroid nodules. Veracyte is also developing Afirma Malignant GEC test. It serves endocrinologists, radiologists, and head and neck specialists. Veracyte, Inc. is headquartered in South San Francisco, California.

Key Statistics

Overview:

Market Capitalization, $K 3,038,000
Enterprise Value, $K 2,821,550
Shares Outstanding, K 77,500
Annual Sales, $ 361,050 K
Annual Net Income, $ -74,400 K
Last Quarter Sales, $ 115,860 K
Last Quarter Net Income, $ 15,160 K
EBIT, $ -11,520 K
EBITDA, $ 15,670 K
60-Month Beta 1.67
% of Insider Shareholders 1.30%
Float, K 76,493
% Float 98.70%
Short Volume Ratio 0.32

Growth:

1-Year Return 54.85%
3-Year Return -5.68%
5-Year Return 36.49%
5-Year Revenue Growth 292.40%
5-Year Earnings Growth 54.84%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.19 on 11/06/24
Next Earnings Date N/A
Earnings Per Share ttm 0.43
EPS Growth vs. Prev Qtr -36.67%
EPS Growth vs. Prev Year 733.33%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

VCYT Ratios

Ratio
Price/Earnings ttm 91.05
Price/Earnings forward 158.18
Price/Earnings to Growth N/A
Return-on-Equity % 3.02%
Return-on-Assets % 2.80%
Profit Margin % -20.61%
Debt/Equity 0.00
Price/Sales 8.40
Price/Cash Flow 421.82
Price/Book 2.56
Book Value/Share 15.31
Interest Coverage -0.70
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar